BioMed Research International / 2020 / Article / Tab 2

Review Article

A Systematic Review of the Current Hepatitis B Viral Infection and Hepatocellular Carcinoma Situation in Mediterranean Countries

Table 2

HBV genotypes and subgenotypes in the different Mediterranean countries.

HBV genotypeHBV subgenotypeReferences

MoroccoD (97.5%), A (2.5%)[16]
D (100%)[18, 23]
D (90.45%), A (5.9%), E (0.5%), and mixed (A/D and D/F) (3.17%)D7 (63.3%), D1 (32.7%), D4 (2%), D5 (2%), and A2[24]

AlgeriaD (93%), A (5%), and E (2%)[34]
D (86.5%) and A (11.76%)D7 (43.5%), D3 (24.75%), D1 (16.8%), D2 (14.85%), and A2 (11.76%)[35]

TunisiaD (80%), A (9%), and E (8%)D7[40]
D (84.75%), A (0.6%), B (0.6%), C (1.82%), and 20 mixed genotypes (12.2%)[41]
D (96%), A (4%)D1 (55%), D7 (41%), and D3 (3%)[42]

LibyaD (90%), A (1.7%), E (1.7%), and D/E (6.7%)ND[51]

EgyptD (100%)[58]
D (87%) and mixed D/F (13%)[59]
E (50%), D (21.43%), and coinfection D/E (28.57%)D1 (21.43%)[57]
D (37.1%) and B (25.7%)[61]

SyriaD (97%)ND[67]
D (100%)[68]

LebanonD (100%)D1 (57.38%) and D2 (11.48%)[72]

Palestine/IsraelHBV/HDV: D (100%)D2 (66.7%), D1 (16.7%), and D3 (16.7%)[75]
HBV: D (88.9%), A (7.4%), and C (3.7%)D1 (59.3%), D2 (18.5%), D3 (11.1%), and A1, A2, and C2 (3.7%)
D (92.5%) and A (7.5%)D1 (90%), D3 (2.5%), and A2 (7.5%)[76]

FranceGND[84]
D (29%), A (24%), C (11%), and E (10%)[85]
D (27%), A (24%), E (13%), C (12%), B (7%), and mixed genotypes (16%)[86]

SpainA (52%), D (35%), and F (7%)D4 (59%), D2 (30%), D3 (7%), and D1 (4%)[94]
D (64.6%)[95]

ItalyD (95%)[107]
D (90%)[108]
D (53%), A (44%), and E (3%)D2[109]
D (49%), A (45%), and F (6%)[110]

TurkeyD (93.04%)D2 (94.6%), D1 (3.9%), and D2+deletion (1.5%)[117]
D (88.7%)D2 (78%-85.9%), D2+deletion (8.9%), D1 (3.9%) and (1.3%)[118]
D (100%)[119]
D (99.1%)[115]

GreeceD (100%)ND[125]
D (98%), A (1%), B (0.5%), and C (0.5%)[126]

CroatiaD (80%), A (8%), and mixed genotypes 12%ND[132]

ND: no data.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.